Eikon Therapeutics, Inc.

NasdaqGS:EIKN Stock Report

Market Cap: US$529.6m

Eikon Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:EIKN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
06 Feb 26BuyUS$38,119,680The Column Group, LLCCompany2,117,760US$18.00
04 Feb 26BuyUS$1,999,998Kenneth FrazierIndividual111,111US$18.00
04 Feb 26BuyUS$4,999,968Lux Capital Management, LLCCompany277,776US$18.00
04 Feb 26BuyUS$999,990Foresite Capital Management, LLCCompany55,555US$18.00

Insider Trading Volume

Insider Buying: EIKN insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of EIKN?
Owner TypeNumber of SharesOwnership Percentage
Institutions130,3130.241%
Private Companies1,720,7073.19%
Sovereign Wealth Funds2,816,7145.22%
Individual Insiders3,190,2905.91%
VC/PE Firms18,886,35835%
General Public27,239,95550.5%

Dilution of Shares: EIKN only recently listed within the past 12 months

Top Shareholders

Top 13 shareholders own 49.54% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
11.1%
Lux Capital Management, LLC
5,972,786US$58.6m597,000,000%55.76%
10.7%
The Column Group, LLC
5,780,143US$56.7m64,200%30.04%
7.49%
Foresite Capital Management, LLC
4,041,687US$39.6m0%3.85%
5.73%
Innovation Endeavors LLC
3,091,742US$30.3m309,000,000%94.34%
5.22%
Abu Dhabi Investment Authority
2,816,714US$27.6m0%0.11%
3.19%
Catalyst4, Inc
1,720,707US$16.9m0%no data
3.08%
Hoi Shuen Chau
1,662,859US$16.3m166,000,000%no data
2.73%
Roger Perlmutter
1,475,856US$14.5m824%no data
0.24%
The Vanguard Group, Inc.
129,060US$1.3m0%no data
0.096%
Alfred Bowie
51,572US$505.9k0%no data
0.0023%
BlackRock, Inc.
1,253US$12.3k0%no data
0%
Roy Baynes
2US$0100%no data
0%
Kenneth Frazier
1US$00%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/29 07:44
End of Day Share Price 2026/03/27 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eikon Therapeutics, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Imogen MansfieldCantor Fitzgerald & Co.
Lut Ming ChengJ.P. Morgan